DK1608745T3 - FVII eller FVIIa-Varianter - Google Patents
FVII eller FVIIa-VarianterInfo
- Publication number
- DK1608745T3 DK1608745T3 DK04722232T DK04722232T DK1608745T3 DK 1608745 T3 DK1608745 T3 DK 1608745T3 DK 04722232 T DK04722232 T DK 04722232T DK 04722232 T DK04722232 T DK 04722232T DK 1608745 T3 DK1608745 T3 DK 1608745T3
- Authority
- DK
- Denmark
- Prior art keywords
- fvii
- variants
- fviia variants
- rhfviia
- hfviia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45654703P | 2003-03-20 | 2003-03-20 | |
US47970803P | 2003-06-19 | 2003-06-19 | |
PCT/DK2004/000193 WO2004083361A2 (en) | 2003-03-20 | 2004-03-22 | FVII OR FVIIa VARIANTS |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1608745T3 true DK1608745T3 (da) | 2009-06-15 |
Family
ID=33032721
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09075170.2T DK2085470T3 (da) | 2003-03-20 | 2004-03-22 | FVII- eller FVIIa-varianter |
DK04722232T DK1608745T3 (da) | 2003-03-20 | 2004-03-22 | FVII eller FVIIa-Varianter |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09075170.2T DK2085470T3 (da) | 2003-03-20 | 2004-03-22 | FVII- eller FVIIa-varianter |
Country Status (10)
Country | Link |
---|---|
US (2) | US7771996B2 (da) |
EP (2) | EP1608745B1 (da) |
JP (2) | JP4847856B2 (da) |
AT (1) | ATE431403T1 (da) |
AU (2) | AU2004221761B2 (da) |
CA (1) | CA2519873C (da) |
DE (1) | DE602004021099D1 (da) |
DK (2) | DK2085470T3 (da) |
ES (2) | ES2386010T3 (da) |
WO (1) | WO2004083361A2 (da) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7247708B2 (en) | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
DK1257295T3 (da) | 2000-02-11 | 2009-08-10 | Bayer Healthcare Llc | Faktor VII eller VIIA-lignende molekyler |
US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7812132B2 (en) | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
DK1499719T3 (da) * | 2002-04-30 | 2011-02-28 | Bayer Healthcare Llc | Faktor VII- eller VIIa-polypeptidvarianter |
WO2004083361A2 (en) | 2003-03-20 | 2004-09-30 | Maxygen Holdings Ltd. | FVII OR FVIIa VARIANTS |
AU2004247799B2 (en) * | 2003-06-19 | 2009-12-03 | Bayer Healthcare Llc | Factor VII or VIIa Gla domain variants |
DK1781782T3 (da) | 2004-08-17 | 2010-08-23 | Csl Behring Gmbh | Modificerede vitamin K-afhængige polypeptider |
EP1893230A2 (en) * | 2005-04-26 | 2008-03-05 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
WO2006134173A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
ES2397851T3 (es) | 2005-07-13 | 2013-03-11 | Novo Nordisk Health Care Ag | Células de inactivación proteínica de la célula huésped para la producción de proteínas terapéuticas |
EP1924689B1 (en) | 2005-09-01 | 2014-08-13 | Novo Nordisk Health Care AG | Hydrophobic interaction chromatography purification of factor vii polypeptides |
WO2007031559A2 (en) | 2005-09-14 | 2007-03-22 | Novo Nordisk Health Care Ag | Human coagulation factor vii polypeptides |
ES2399138T3 (es) * | 2006-03-16 | 2013-03-26 | Stellaris Pharmaceuticals Aps | Tratamiento local con factor VII |
JP5570809B2 (ja) | 2006-09-01 | 2014-08-13 | ノボ ノルディスク ヘルス ケア アーゲー | 修飾タンパク質 |
SI2147096T1 (sl) * | 2007-04-13 | 2015-07-31 | Catalyst Biosciences, Inc., | Modificirani polipeptidi faktorja VII in njihove uporabe |
AU2013204377B2 (en) * | 2007-04-13 | 2015-07-16 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides and uses thereof |
TWI538916B (zh) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
TWI595004B (zh) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
PL2938351T3 (pl) * | 2012-12-24 | 2020-03-31 | Coagulant Therapeutics Corporation | Krótko działające polipeptydy czynnika VII |
EP3687580A1 (en) | 2017-09-27 | 2020-08-05 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising active cells |
WO2019195056A1 (en) | 2018-04-04 | 2019-10-10 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising stem cells |
CA3096038A1 (en) | 2018-04-04 | 2019-10-10 | Sigilon Therapeutics, Inc. | Implantable particles and related methods |
UY38389A (es) | 2018-09-27 | 2020-04-30 | Sigilon Therapeutics Inc | Dispositivos implantables para terapia celular y métodos relacionados |
WO2021030787A1 (en) | 2019-08-15 | 2021-02-18 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
WO2024081309A1 (en) | 2022-10-11 | 2024-04-18 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
WO2024081310A1 (en) | 2022-10-11 | 2024-04-18 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
US5180583A (en) * | 1985-11-26 | 1993-01-19 | Hedner Ulla K E | Method for the treatment of bleeding disorders |
US5258288A (en) * | 1986-07-25 | 1993-11-02 | Genzyme Corporation | Vector containing DNA encoding mature human protein S |
DK323587D0 (da) | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
PT87688B (pt) | 1987-06-12 | 1992-09-30 | Hoechst Japan | Processo para a preparacao de proteina hibrida c |
US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US5648254A (en) * | 1988-01-15 | 1997-07-15 | Zymogenetics, Inc. | Co-expression in eukaryotic cells |
JPH0246296A (ja) | 1988-08-09 | 1990-02-15 | Hoechst Japan Ltd | 雑種プロテインc及びその製造方法 |
US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
US5041376A (en) * | 1988-12-09 | 1991-08-20 | The Board Of Regents Of The University Of Texas System | Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
US5077214A (en) | 1989-07-07 | 1991-12-31 | The Texas A&M University System | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells |
US5580560A (en) | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
US5225537A (en) * | 1989-12-29 | 1993-07-06 | Zymogenetics, Inc. | Methods for producing hybrid phospholipid-binding proteins |
HUT63459A (en) | 1990-01-26 | 1993-08-30 | Immuno Ag | Blood factors produced by recommbinant process, process for expressing them, as well as recombinant vaccine viruses used in the process |
AU651573B2 (en) * | 1990-01-29 | 1994-07-28 | Novo Nordisk Health Care Ag | Anticoagulant proteins |
US5583107A (en) | 1990-09-04 | 1996-12-10 | Cor Therapeutics, Inc. | Agents affecting thrombosis and hemostasis |
US5531916A (en) * | 1990-10-03 | 1996-07-02 | E. I. Du Pont De Nemours And Company | Hydrofluorocarbon cleaning compositions |
WO1992009698A1 (en) * | 1990-11-26 | 1992-06-11 | Genetics Institute, Inc. | Expression of pace in host cells and methods of use thereof |
WO1994027631A1 (en) | 1993-05-21 | 1994-12-08 | Zymogenetics, Inc. | Modified factor vii |
US5833982A (en) * | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
US5788965A (en) | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
CA2103546C (en) | 1991-02-28 | 2002-10-01 | Kathleen L. Berkner | Modified factor vii |
US5861374A (en) * | 1991-02-28 | 1999-01-19 | Novo Nordisk A/S | Modified Factor VII |
US5817788A (en) * | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
JPH0720127A (ja) * | 1993-05-07 | 1995-01-24 | Eisai Co Ltd | 各種pivkaの測定方法および測定試薬 |
DE19531637A1 (de) * | 1995-08-28 | 1997-03-06 | Immuno Ag | Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung |
US5837843A (en) * | 1996-11-08 | 1998-11-17 | Oklahoma Medical Research Foundation | Modified protein C |
DE69735597T2 (de) * | 1996-11-08 | 2006-12-21 | Oklahoma Medical Research Foundation, Oklahoma | Verwendung eines modifizierten protein-c |
IL130908A0 (en) * | 1997-01-22 | 2001-01-28 | Univ Texas | Tissue-factor (tf) compositions for coagulation and tumor treatment |
ATE200030T1 (de) | 1997-01-29 | 2001-04-15 | Polymasc Pharmaceuticals Plc | Pegylationsverfahren |
CA2279986A1 (en) | 1997-02-06 | 1998-08-13 | Novo Nordisk A/S | Polypeptide-polymer conjugates having added and/or removed attachment groups |
AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
US6475725B1 (en) * | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
BR9812267B1 (pt) | 1997-07-14 | 2013-11-26 | Hormônio de crescimento recombinante. | |
ES2339196T3 (es) | 1997-07-18 | 2010-05-17 | Novo Nordisk Health Care Ag | Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente. |
WO2001082943A2 (en) * | 2000-05-03 | 2001-11-08 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor vii |
US6693075B1 (en) * | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6017882A (en) | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6747003B1 (en) * | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
IL139286A (en) | 1998-04-28 | 2005-12-18 | Applied Research Systems | Polyol-ifn-beta conjugates, their preparation and use |
AT408613B (de) | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
ATE390441T1 (de) | 1998-10-30 | 2008-04-15 | Novozymes As | Niedrigallergene proteinvarianten |
CN1325443A (zh) | 1998-10-30 | 2001-12-05 | 诺沃奇梅兹有限公司 | 具有减弱的变应原性的糖基化蛋白 |
WO2000028065A1 (en) | 1998-11-06 | 2000-05-18 | Novo Nordisk A/S | Method for the production of fvii |
WO2000054787A1 (en) | 1999-03-16 | 2000-09-21 | The Children's Hospital Of Philadelphia | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
DK1257295T3 (da) | 2000-02-11 | 2009-08-10 | Bayer Healthcare Llc | Faktor VII eller VIIA-lignende molekyler |
US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
JP4455802B2 (ja) | 2000-05-03 | 2010-04-21 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | ヒト第vii凝固因子変異型 |
US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
CA2420892A1 (en) * | 2000-09-13 | 2002-03-21 | Novo Nordisk A/S | Human coagulation factor vii variants |
AU2001287550B2 (en) * | 2000-09-13 | 2007-03-22 | Novo Nordisk Health Care Ag | Human coagulation factor VII variants |
BR0114373A (pt) * | 2000-10-02 | 2004-02-17 | Novo Nordisk As | Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante |
WO2002038162A1 (en) | 2000-11-09 | 2002-05-16 | The Scripps Research Institute | MODIFIED FACTOR VIIa |
CZ20032454A3 (en) | 2001-03-22 | 2004-03-17 | Novo Nordisk Health Care Ag | Coagulation factor vii derivative |
ATE532858T1 (de) | 2001-09-27 | 2011-11-15 | Novo Nordisk Healthcare Ag | Menschliche gerinnungsfaktor-vii-polypeptide |
AU2002336919A1 (en) | 2001-11-02 | 2003-05-12 | Novo Nordisk Health Care Ag | Human coagulation factor vii polypeptides |
BR0215216A (pt) | 2001-12-21 | 2004-11-16 | Novo Nordisk Healthcare Ag | Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii |
DK1499719T3 (da) | 2002-04-30 | 2011-02-28 | Bayer Healthcare Llc | Faktor VII- eller VIIa-polypeptidvarianter |
AU2003266931B2 (en) * | 2002-09-30 | 2010-01-21 | Bayer Healthcare Llc | FVII or FVIIa variants having increased clotting activity |
WO2004083361A2 (en) | 2003-03-20 | 2004-09-30 | Maxygen Holdings Ltd. | FVII OR FVIIa VARIANTS |
AU2004247799B2 (en) | 2003-06-19 | 2009-12-03 | Bayer Healthcare Llc | Factor VII or VIIa Gla domain variants |
WO2005023308A1 (en) * | 2003-09-05 | 2005-03-17 | Maxygen Holdings Ltd. | Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins |
-
2004
- 2004-03-22 WO PCT/DK2004/000193 patent/WO2004083361A2/en active Application Filing
- 2004-03-22 AT AT04722232T patent/ATE431403T1/de not_active IP Right Cessation
- 2004-03-22 AU AU2004221761A patent/AU2004221761B2/en not_active Ceased
- 2004-03-22 ES ES09075170T patent/ES2386010T3/es not_active Expired - Lifetime
- 2004-03-22 JP JP2006504332A patent/JP4847856B2/ja not_active Expired - Fee Related
- 2004-03-22 EP EP04722232A patent/EP1608745B1/en not_active Expired - Lifetime
- 2004-03-22 CA CA2519873A patent/CA2519873C/en not_active Expired - Fee Related
- 2004-03-22 DE DE602004021099T patent/DE602004021099D1/de not_active Expired - Lifetime
- 2004-03-22 DK DK09075170.2T patent/DK2085470T3/da active
- 2004-03-22 EP EP09075170A patent/EP2085470B1/en not_active Expired - Lifetime
- 2004-03-22 ES ES04722232T patent/ES2327044T3/es not_active Expired - Lifetime
- 2004-03-22 US US10/549,506 patent/US7771996B2/en not_active Expired - Fee Related
- 2004-03-22 DK DK04722232T patent/DK1608745T3/da active
-
2010
- 2010-03-25 AU AU2010201201A patent/AU2010201201A1/en not_active Abandoned
- 2010-05-05 US US12/774,560 patent/US20100330669A1/en not_active Abandoned
-
2011
- 2011-07-22 JP JP2011160400A patent/JP2012095641A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2004083361A3 (en) | 2004-11-04 |
AU2010201201A1 (en) | 2010-04-15 |
EP2085470B1 (en) | 2012-05-16 |
WO2004083361A2 (en) | 2004-09-30 |
DK2085470T3 (da) | 2012-08-06 |
JP2006521098A (ja) | 2006-09-21 |
JP4847856B2 (ja) | 2011-12-28 |
ES2386010T3 (es) | 2012-08-07 |
ATE431403T1 (de) | 2009-05-15 |
US7771996B2 (en) | 2010-08-10 |
EP1608745A2 (en) | 2005-12-28 |
CA2519873C (en) | 2012-12-18 |
EP2085470A1 (en) | 2009-08-05 |
ES2327044T3 (es) | 2009-10-23 |
JP2012095641A (ja) | 2012-05-24 |
AU2004221761B2 (en) | 2010-01-07 |
US20070054366A1 (en) | 2007-03-08 |
DE602004021099D1 (de) | 2009-06-25 |
US20100330669A1 (en) | 2010-12-30 |
AU2004221761A1 (en) | 2004-09-30 |
CA2519873A1 (en) | 2004-09-30 |
EP1608745B1 (en) | 2009-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1608745T3 (da) | FVII eller FVIIa-Varianter | |
DE60143606D1 (de) | Xylanase-varianten mit veränderter sensitivität gegenüber xylanase-hemmstoffen | |
NO2017028I1 (no) | eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet. | |
ATE462006T1 (de) | Isoform des vegfs | |
NZ606504A (en) | Modified proteases that inhibit complement activation | |
IS2552B (is) | Hindrar á Þátt Xa og aðra serín próteasa sem tengjast storknunarkeðjuverkun | |
DK1549677T3 (da) | FVII- eller FVIIa-varianter med forøget koagulationsaktivitet | |
WO2007031559A3 (en) | Human coagulation factor vii polypeptides | |
NO20063624L (no) | FC region varianter | |
ATE394464T1 (de) | Flüssige bleichaktivatorzusamensetzung | |
CY1111626T1 (el) | ΠΑΡΑΛΛΑΓΕΣ ΠΟΛΥΠΕΠΤΙΔΙΩΝ ΠΑΡΑΓΟΝΤΑ VII ´H VIIa | |
ATE365210T1 (de) | Glykosylierte proteine mit reduzierter allergenität | |
CY1110185T1 (el) | Τροποποιημενη πρωτεϊνη vp1-καψιδιου του παρβοϊου β19 | |
WO2006114105A3 (en) | Use of modified factor vii for treating bleeding | |
DE60232653D1 (de) | Pharmazeutisch wirksame uridinester | |
ATE350470T1 (de) | Durch thrombin spaltbare chimäre proteine | |
HUP0401658A2 (hu) | Humán szöveti faktor ellenanyagok | |
TR199902751T2 (xx) | Proteaz inhibit�rleri. | |
ATE330017T1 (de) | Kallikrein gen | |
ATE515248T1 (de) | Dentalzusammensetzung mit einem enzym | |
DE602007001519D1 (de) | Zusammensetzung mit mehreren botulinumtoxinen | |
ATE452002T1 (de) | Trennscheibe | |
DK2284251T3 (da) | Alkalisk protease med forøget specifik aktivitet over for casein | |
ATE435657T1 (de) | Therapeutische zubereitung von hochreinem fviia und verfahren zu dessen gewinnung | |
ATE323722T1 (de) | Antimikrobiell wirkendes peptid |